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Photodynamic therapy (PDT) is a promising new approach for the
treatment of superficially localised tumours. This modality involves
local or systemic delivery of a photosensitizer (PS), followed by
tissue illumination with light of appropriate wavelength. This light
causes activation of PS which produces activated oxygen molecules
(singlet oxygen), responsible for tumour necrosis. This tumour
necrosis is the result of direct and indirect (occlusion of tumour
blood vessels, inflammatory reaction) damage to the tumours cells
(Dougherty et al, 1998). One of the limitations of this approach is
the low selectivity of the PS for tumour tissues. An attractive option
to overcome this problem is to couple PS on monoclonal antibodies
(MAb) directed against tumour-associated antigens (Goff et al,
1994; Mew et al, 1983; Oseroff et al, 1986; Vrouenraets et al, 1999).
In a previous study, we described newly developed photoimmuno-
conjugates synthesized with an anti-CEA MAb and an hydrophylic
PS, aluminium tetrasulfophthalocyanine, AlPcS4A1 (Carcenac et al,
1999). These conjugates were phototoxic in vitro on CEA-
expressing cells, but this photo-induced cytotoxicity was not suffi-
cient to induce tumour necrosis in vivo. We hypothesised that this
photo-induced cytotoxicity could be enhance by using a MAb able
to deliver the PS intracellularly. 
In the present study, we coupled the same PS to an internalising
antibody, FSP77, directed against ErbB2. We compared its 
photo-induced cytotoxicity to that of a non-internalising conjugate
directed against CEA on an original cell line, SKOv3-CEA-1B9,
expressing the two target antigens, ErbB2 and CEA. Our results
confirmed the hypothesis since the anti-Erb2 conjugate was about
10 times more efficient than the anti-CEA conjugate for killing the
target cells. 
MATERIAL AND METHODS 
Photosensitizer 
Tetrasulfonated aluminium phthalocyanine (AlPcS4) was converted
to the tetrasulfonyl chloride derivative and reacted with 6-amino-
hexanoic acid to yield the monosulfonamide derivative AlPcS4A1,
bearing a free carboxyl group. After activation and chromato-
graphic purification the material was lyophilized and stored 
at –20˚C prior to use (Brasseur et al, 1999; Carcenac et al, 1999). 
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Three murine monoclonal antibodies were used for conjugation
with the activated AlPcS4A1: the anti-CEA MAb 35A7, which was
used for immunophotodetection (IPD) (Gutowski et al, 2001;
Pèlegrin et al, 1991) and immunophototherapy (IPT) studies
(Carcenac et al, 1999); MAb FSP77, which bind specifically to the
extracellular domain of the human ErbB2 receptor (Harwerth et al,
1992); and MAb Px purified from mouse myeloma P3-X63
(Kohler et al, 1976), which was used as reference IgG1 for the
synthesis of a non-specific immunoconjugate. All the MAbs were
purified from mouse ascites using ammonium sulfate precipitation
and ion exchange chromatography. 
Preparation of MAb-AlPcS4A1 conjugates 
MAbs were coupled to AlPcS4A1 by the carbodiimide method as
described (Brasseur et al, 1999; Carcenac et al, 1999). Briefly,
the monocarboxylic group of AlPcS4A1 was first activated with 
1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride
(EDC, Aldrich) and N-hydroxysulfosuccinimide (sulfo-NHS,
Pierce). The activated photosensitizer was added drop-wise to a
MAb solution (1 mg/ml) in 0.5 M sodium bicarbonate buffer, pH
9.0. The mixture was kept for 18 h at 4˚C in the dark to allow
complete coupling of the activated AlPcS4A1 via formation of
amide bonds with the free amino groups of the MAb. The conju-
gate was separated from excess dye by gel filtration chromatog-
raphy over a Sephadex G25 column (Pharmacia, Uppsala,
Sweden) equilibrated in phosphate-buffered saline (PBS, pH 7.4)
containing 0.1% azide. The molar AlPcS4MAb ratios were esti-
mated by spectroscopy using the following equations: C(MAb) =
[A280 nm – (0.5 × A340 nm)] / ε MAb and C(PS) = A340 nm / ε PS with ε MAb =
195,000 M–1 cm–1 and ε PS = 52,400 M–1 cm–1, respectively. This
method allowed to calculate an approximate number of dye mole-
cules per Mab molecule. Integrity of the MAb-AlPcS4A1 conju-
gates was analyzed by electrophoresis (7.5% SDS-PAGE under
nonreducing conditions) in comparison with the native unconju-
gated MAb. 
MAbs and conjugates were radioiodinated using the Iodogen
method (1,3,4,6-tetrachloro-3α , 6α -diphenylglycoluryl, Sigma),
to arrive at a final specific activity of about 2 µ Ci of 125I per µ g
protein (1 µ Ci = 37 GBq) as described (Carcenac et al, 1999).
Immunoreactivity of the different 125I-labeled conjugates was
compared to that of the corresponding 125I-labeled MAbs in a
direct binding assay using the relevant antigen coupled to
Sepharose-CNBR (Pharmacia) (Carcenac et al, 1999). 
Cell line and transfection 
The human ovarian carcinoma cell line, SKOv3, purchased from
the American Type Culture Collection (HTB-77, Rockville, MD,
USA), was maintained according to recommended procedures.
The SKOv3 cells were transfected with pRc/CMV/CEA-cDNA
(Pèlegrin et al, 1992) using a mammalian transfection kit
(Stratagene, La Jolla, CA, USA). Three µ g of DNA were precipi-
tated with calcium phosphate according to the manufacturer’s
instructions and incubated for 16 h with about 3 × 106 non-
confluent adherent carcinoma cells. Fresh culture medium was then
added and after a further 24 h incubation, the cells were harvested,
divided in two 75 cm2 flasks and grown for 24 h before adding the
Geneticin analogue G418 (Gibco, Paisley, UK) at a concentration
of 500 µ g/ml. This concentration of G418 was shown to be 5 times
the minimal lethal dose for non-transfected SKOv3 cells. Cells
resistant to G418 were expanded and tested for CEA expression by
flow cytometry using the fluorescence-activated cell sorter (FACS,
Becton Dickinson, Mountain View, CA, USA). CEA-positive cells
were sorted and cloned by limiting dilution. Among the different
CEA-expressing clones obtained, clone 1B9 was named SKOv3-
CEA-1B9 and used for further experiments. 
Internalisation of MAb-(AlPcS4A1)n conjugates 
Cells SKOv3-CEA-1B9 monolayers were obtained by seeding 3–5
× 104 cells in 3 ml of DMEM containing 10% foetal calf serum and
supplemented with L-glutamine, on 22-mm square glass cover-
slips deposited in 35-mm Petri dishes. Three days after culture
initiation, cells were washed with PBS, and incubated at 4˚C or
37˚C during 30, 90 and 240 min with the different conjugates
FSP77-(AlPcS4A1)6, 35A7-(AlPcS4A1)8 and Px-(AlPcS4A1)9 at 10
µ g/ml of Mab. The cells were washed with PBS, and fixed for 20
to 30 min in 3.7% p-formaldehyde in PBS, washed with PBS, and
permeabilized with acetone at –20˚C for 30 s. After washes with
PBS, the cells were incubated with fluorescein isothiocyanate
(FITC)-conjugated anti-mouse Ig F(ab’)2 fragment (Selenus,
AMRAD) during 1 h in the dark. Nuclei were counterstained using
DAPI (4,6 diamidino 2–2 phenylindoldihydrochloride, Sigma).
The coverslips were deposited on microscope slides with
VECTASHIELD®Mounting Medium for fluorescence (VECTOR
Laboratories Inc, Burlingame, CA USA). Mounted slides were
stored at 4˚C protected from light until use. Slides were observed
with an epiillumination fluorescence microscope (Axioplan 2
imaging HBO 100; Zeiss) equiped with a coupled charge device
camera (IAI, Progressive Scan, Japan). Images were obtained at ×
63, using excitation light provided by a mercury vapor lamp.
Analysis of images was performed using appropriate software
(Meta systems isis 4, in situ imaging system). 
In vitro photo-induced cytotoxicity 
The cytotoxic activity of the immunoconjugates FSP77-
(AlPcS4A1)6, 35A7-(AlPcS4A1)8 and Px-(AlPcS4A1)9 was assessed
in the SKOv3-CEA-1B9 cell line. After trypsinization, the cells
were resuspended in phenol red-free RPMI and dispensed in 96-
well plates (20 000 cells/well) and grown for 24 h to allow cells to
attach. Two types of experiments were realized. In the first series,
after removing the growth medium, FSP77-(AlPcS4A1)6, 35A7-
(AlPcS4A1)8 or Px-(AlPcS4A1)9 diluted in phenol red-free RPMI,
were added to the cells in triplicates to the final concentrations
indicated in Figure 3. After a 20 h incubation, unbound immuno-
conjugates were removed by washing twice with medium. Fresh
phenol red-free RPMI was added, and cells were illuminated at
676 nm with a light source consisting of a focalized Xenon
Cermax LX-300F lamp (ILC Technology, Sunnyvale, CA, USA)
at a dose of 50 J/cm2. During illumination, the cells were main-
tained at 37˚C using a Multi-block® Heater (Lab-Line Instruments,
Inc). In the second series, after removing the growth medium,
FSP77–(AlPcS4A1)6, 35A7–(AlPcS4A1)8 or Px-(AlPcS4A1)9 prepared
in phenol red-free RPMI, were added to the cells in triplicates to a
concentration of 1.25 µ g/ml. After different incubation times (1, 2,
4 and 8 h), unbound immunoconjugates were removed by washing
twice with medium. Fresh phenol red-free RPMI was added and
cells were illuminated in the same conditions as in experiment one.
1788 M Carcenac et al
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analysed using the tetrazolium salt 3-[(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide]) (Sigma) MTT colorimetric
assay (Merlin et al, 1992). Briefly, 50 µ l of a 0.5% MTT solution
was added to each well and incubated for 4 h at 37˚C to allow
MTT metabolization. The crystals formed were dissolved by
adding 100 µ l per well of isopropylic alcohol, HCl 1N. The
absorbance at 540 nm was measured on a Microtiter® Plate Reader
MRX (Dynatech Laboratories). The results were expressed with
respect to control values (cells without any treatment). For all exper-
iments, all the conjugates were not toxic without illumination.
RESULTS 
In vitro characterization of MAb-AlPcS4A1 conjugates 
Conjugates substituted with 6 to 9 moles of AlPcS4 per mole of
MAb were obtained by using an initial molar ratio of 40 in the
reaction mixture. The percentage of aggregates determined by gel
filtration on a Sephacryl 300 column (Pharmacia) was found to be
< 10%. The immunoreactivity of all the conjugates determined in a
direct binding assay was shown to be similar to that observed with
the corresponding unconjugated MAb. SDS-PAGE analysis of the
conjugates demonstrated a single protein band with an apparent
molecular weight comparable to that of native unconjugated MAb
(data not shown). 
Characterization of the SKOv3-CEA-1B9 cell lline 
Transfection of the full-length CEA-cDNA into the ErbB2
expressing SKOv3 cell line gave around 15% CEA expressing
cells after selection with the neomycin analogue G418. The CEA
expressing cells were sorted by FACS and cloned by limiting dilu-
tions. For five clones, CEA expression was comparable to ErbB2
expression. Clone 1B9 was used for the following experiments.
Expression of CEA and ErbB2 determined by FACS is shown in
Cancer immunophototherapy 1789
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Figure 1 Flow cytometry analysis of the newly developed SKOv3-CEA-1B9 cell line, and control cell lines LS174T and SKOv3, using anti-CEA MAb or anti-
ErbB2 MAb. LS174T is a human colon carcinoma cell line selected for high CEA expression and SKOv3, human ovarian carcinoma was used for transfection.
Irrelevant control fluoresceinated IgG (——; no shading), fluoresceinated anti-CEA MAb or anti-ErbB2 MAb (——; black shading) Figure 1 for SKOv3-CEA-1B9 as compared with the parental
SKOv3 cell line (high ErbB-2 expression) and a reference human
colon carcinoma cell line LS174T (high CEA expression). The
histograms obtained with the SKOv3-CEA-1B9 cells gave a
sharper peak of CEA expression than that obtained with the
LS174T cell line, suggesting that the transfected cells gave a more
homogeneous CEA expression because they were stably trans-
fected with human CEA cDNA. In the SKOv3-CEA-1B9 cell line,
ErbB2 and CEA antigenic densities were very close with fluores-
cence intensity medians of 500.29 +/– 24.66 and 495.81 +/– 26.73
for ErbB2 and CEA, respectively (Figure 1). 
Internalisation of MAb-(AlPcS4A1)n conjugates 
Analysis of the internalisation of the different conjugates was
performed using an immunofluorescence technique on the
SKOv3-CEA-1B9 cells at 4˚C and 37˚C. Our results confirmed the
internalising properties of the anti-ErbB2 conjugate, FSP77-
(AlPcS4A1)6 as well as the non-internalisation of the anti-CEA
conjugate, 35A7-(AlPcS4A1)8. At 37˚C, binding of the two conju-
gates on SKOv3-CEA-1B9 cells was shown after a 30 min incuba-
tion time (Figure 2A and D). The intracellular localisation of the
FSP77-(AlPcS4A1)6 conjugate was seen after the 90 min incuba-
tion time (Figure 2B) and intracellular vesicles containing the
conjugate were obvious after 240 min (Figure 2C). During this
kinetic analysis, the 35A7-(AlPcS4A1)8 conjugate did not show
any intracellular localisation (Fig 2D–F). At 4˚C, no internalisa-
tion was visualised with the FSP77-(AlPcS4A1)6 conjugate which
gave a membrane binding comparable to that obtained with 35A7-
(AlPcS4A1)8. No cellular binding was observed with the irrelevant
conjugate, Px-(AlPcS4A1)9. 
In vitro photo-induced cytotoxicity 
The in vitro cytotoxicity of immunoconjugates was evaluated on
SKOv3-CEA-1B9, using an illumination at a light dose of 50
J/cm2. In a first series of experiments, cells were incubated 20 h
with five different concentrations of photosensitizer ranging from
0.0025 µ g/ml to 2.50 µ g/ml (Figure 3). The FSP77-(AlPcS4A1)6
induced 96% growth inhibition of the cells for the AlPcS4A1
concentration of 2.50 µ g/ml. At the same photosensitizer concen-
tration, 35A7-(AlPcS4A1)8 generated a 68% growth inhibition.
However, the FSP77-(AlPcS4A1) 6 conjugate gave a 51% growth
inhibition for an AlPcS4A1 concentration as low as 0.04 µ g/ml
after the same incubation time and exposure to the same light dose
(Figure 3). Experiments realised with native (unconjugated) Mab
FSP77 or free AlPcS4A1, with or without light illumination did not
give any cell growth inhibition. 
In a second series of experiments, SKOv3-CEA-1B9 cells were
incubated for 1, 2, 4 or 8 h with a constant concentration of
AIPcS4A1  of 1.25 µ g/ml (Figure 4). The FSP77-(AlPcS4A1)6
conjugate gave 67%, 76%, 86% and 96% growth inhibition after 1,
2, 4 and 8 h of incubation, respectively. No photo-induced cyto-
toxicity was observed with the 35A7-(AlPcS4A1)8 conjugate up to
4 h of incubation. With a 8 h incubation time, the 35A7-
(AlPcS4A1)8 conjugate gave a 72% growth inhibition. 
DISCUSSION 
Immunophototherapy is an attractive modality to enhance photody-
namic therapy efficacy by increasing the tumor-to-normal tissues
ratios of the photosensitisers. In a previous report, we described the
preparation and characterisation of MAb-phthalocyanine conjugates
directed against CEA (Carcenac et al, 1999). Despite a phototoxic
activity in vitro on LoVo cells (91% growth inhibition at 2.5 µ g/ml
AlPcS4A1 concentration) and a high tumour uptake (up to 30% ID/g
tumour 24 h post-injection), the anti-CEA 35A7-AlPcS4A1 conju-
gates had a limited in vivo anti-tumour activity. For this reason, we
decided to evaluate MAb-dye conjugates able to deliver photosensi-
tisers inside the cells. Internalisation of such conjugates can be
obtained by (i) a chemical modification of the conjugate or (ii) the
internalising character of target antigen. We demonstrate here that
monoclonal antibody–phthalocyanine conjugates directed against
an internalising antigen, ErbB2, are more phototoxic than conju-
gates directed against a non-internalising antigen, CEA. 
Since 1996, the group of Hasan has explored the first possibility
using poly-L-lysine linkers to prepare cationic chlorine6 (ce6)-
antibodies conjugates and succinylated poly-L-lysine linkers to
obtain anionic conjugates (Del Governatore, 2000a, 2000b; Duska
et al, 1997; Hamblin et al, 1996,2000). In the first part of their work,
these authors demonstrated that a cationic conjugate prepared with
ce6 and F(ab’)2 fragments from MAb OC125 induced in vitro a
higher photo-induced cytotoxicity on the human ovarian cancer cell
line NIH-OVCAR-5 than an anionic conjugate (Hamblin et al,
1996). The positive charges of the cationic conjugate allowed a
higher cellular uptake being responsible for the enhanced photo-
induced cytotoxicity. When the NIH-OVCAR-5 cells were used to
induce a peritoneal carcinomatosis in nude mice, the cationic
conjugate was shown to deliver about 2.6 times more ce6 in tumor
nodules 24 h post i.p. injection than the anionic conjugate as deter-
mined by fluorescence (28.3 ± 9.6 vs 11.0 ± 5.0 × 10–6 fluores-
cence A.U per gram tumour) (Duska et al, 1997). However, due to
the chemical modification, the tumour uptake of the conjugate was
lower than that of the native F(ab’)2 fragments. Twenty four hours
post injection, the %ID/g tumour was 38.1 ± 2.9, 17.1 ± 1.8 and
3.8 ± 0.9 for the OC125 F(ab’)2, the cationic conjugate and the
anionic conjugate, respectively. Recently, these authors moved to
human colon carcinoma as a target tumour. Using MAb 17.1A,
they confirmed the higher in vitro photo-induced cytotoxicity of a
cationic conjugate as compared to an anionic conjugate on HT29
cells (Del Governatore, 2000b). In vivo, using hepatic metastases
induced with HT29 cells in nude mice, the anionic conjugate
delivered 5 and 8 times more ce6 than the cationic conjugate at 3
and 24 h post-i.v. injection, respectively (Hamblin et al, 2000).
The discrepancy between the in vitro and the in vivo results in this
model was attributed to the use of the i.v. route of injection of the
conjugate which induced a high ce6 uptake in lung and bladder.
Therefore, the authors used the anionic conjugate in an
immunophototherapy study in which the anionic 17.1A-ce6 was
shown to be more efficient than free ce6 to enhance the median
survival time of nude mice bearing HT29 induced liver metastases
(62.5, 77 and 102 days for the control group, the ce6 treated group
and the anionic 17.1A-ce6 conjugate treated group, respectively)
(Del Governatore, 2000a). The overall results of these studies
underlined (i) the potential of chemically modifying MAb with
conjugated dyes to enhance their photo-induced cytotoxicity; (ii)
the technical difficulties inherent to this approach. The cationiza-
tion of MAb-dye conjugates is a chemical modification that is not
related to the antigen specificity of the MAb. It can hence increase
internalisation of the conjugate in different cell types. 
Another approach to deliver phototoxic dyes into cells is the use
of MAb directed against internalising antigens. This strategy was
1790 M Carcenac et al
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suggesting that in vitro a conjugate prepared with the inter-
nalising MAb 425 (anti-EGF-R) was more phototoxic than a 
non-internalising MAb prepared with MAb U36 directed against
the v6 domain of the 200 kDa CD44 splice variant epican
(Vrouenraets et al, 1999). However these results, which were
Cancer immunophototherapy 1791
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Figure 2 Photomicrograph of SKOv3-CEA-1B9 cell line. Cells were grown on coverslips, fixed and stained with anti-mouse Ig FITC conjugated-green
fluorescence and DAPI-blue nuclear stained. Uptake of the FSP77-(AlPcS4A1)6 conjugate is shown after incubation at 37˚C for 30 min (A), 90 min (B) and 
240 min (C). Uptake of the 35A7-(AlPcS4A1)8 conjugate is shown after at 37˚C at 30 min (D), 90 min (E) and 240 min (F) obtained on two different cell lines (A431 for MAb 425 and UM-
SCC-22A for U36), did not take into account the specific photo-
sensitivity of these two cell lines. Furthermore, free mTHPC was
as efficient as MAb 425-mTHPC conjugate in killing A431 cells.
In a second study, the authors used an hydrophilic porphyrin
derivative, TrisMPyP-Φ CO4H, to demonstrate in vitro that inter-
nalising conjugates prepared with MAb 425 and MAb U36
exhibited a higher photo-induced cytotoxicity on A431 cells than
the free dye and a non-internalising conjugate prepared with
MAb E48 directed against a surface antigen expressed by
HNSCC (Vrouenraets et al, 2000). The antigenic density of these
different target antigens on A431 cells as well as the affinity
constants of the different MAbs against their antigen were not
clearly mentioned in the manuscript but these data confirmed the
potential advantage of internalising over non-internalising conju-
gates. The major limitation of the TrisMPyP-Φ CO2H-MAb
conjugates is their poor tumour uptake as compared to the native
MAb. In HNX-OE SCC bearing nude mice, MAb U36 and
conjugates loaded with 1.2, 2.1 and 3.0 TrisMPyP-Φ CO2H per
MAb showed tumour uptake values of 15.5, 8.6, 6.5 and
4.0%ID/g, respectively. 
In the present study, using our AlPcS4A1 hydrophilic photosensi-
tizer, we compared the in vitro photo-induced cytotoxicity of an
internalising (MAb FSP77) to that of a non-internalising conjugate
(MAb 35A7) on the same cell line SKOv3-CEA-1B9. This cell line,
which was derived from the human ovarian cancer SKOv3 by trans-
fection with the CEA cDNA, was shown to express the two target
antigens, ErbB2 and CEA, at the same high level (Figure 1). As
demonstrated by immunofluorescence, the FSP77-(AlPcS4A1)6
conjugate internalised rapidly in SKOv3-CEA-1B9 cells whereas
the 35A7-(AlPcS4A1)8 conjugate did not (Figure 2). The non-
internalising conjugate was phototoxic but the higher photo-induced
cytotoxicity of the internalising conjugate was demonstrated in a
dose dependent experiment (Figure 3) as well as a time dependent
study (Figure 4). These data confirm the advantage of anti-Erb2
FSP77-AlPcS4A1 conjugates over anti-CEA 35A7-AlPcS4A1 conju-
gates for photodynamic applications. The major advantage of our
photosensitizer is that conjugates bearing up to 16 AlPcS4A1per MAb
were shown to give tumour uptake values similar to that obtained
with the native MAb (Carcenac et al, 1999). On the basis of these in
vitro results, anti-ErbB2-AlPcS4A1conjugates are currently evaluated
for their therapeutic potential on breast and ovary carcinoma. 
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